Abstract
Several lines of anatomical, neurochemical, electrophysiological, and behavioral evidence suggest the existence of physiological interactions between neurotensin (NT) and the brain dopaminergic systems. Thus, NT has been shown to exert a neuroleptic-like action and could be implicated in the pathogenesis and treatment of schizophrenia. It is thus of particular importance to develop in vitro cell culture systems as models to study such interactions. Rat adrenal pheochromocytoma PC12 cells, which expressed high levels of tyrosine hydroxylase, were used in the present study. In contrast to rat brain cells in primary cultures, PC12 cells did not express functional NT receptors. However, they were able to express both NTmRNA and NT in response to NGF, forskolin, and dexamethasone. Those neurochemical modifications furthermore may be related to changes in the morphology of the PC12 cells in response to NGF, forskolin, and dexamethasone alone or in combination. These data suggest that PC12 cells may provide a useful model to study in vitro the regulation of both catecholamine and neurotensin phenotypes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baetge E. E., Kaplan B. B., Reis D. J., and Joh T. H. (1981)Proc. Natl. Acad. Sci. USA 78, 1269.
Blaha C. D., Coury A., Fibiger H. C., and Phillips A. G. (1990)Neuroscience 34, 699.
Bradford M. M. (1976)Anal. Biochem. 72, 248.
Brouard A., Pélaprat D., Boja J. W., Carroll F. I., Vial M., Kuhar M. J., et al. (1993)Dev. Brain Res. 75, 13.
Brouard A., Pélaprat D., Dana C., Vial M., Lhiaubet A.-M., and Rostène W. (1992)J. Neurosci. 12, 1409.
Carraway R. E. and Leeman S. E. (1973)J. Biol. Chem. 248, 6854.
Castel M. N., Malgouris C., Blanchard J. C., and Laduron P. M. (1990)Neuroscience 36, 425.
Damon D. H., D'Amore P. A., and Wagner J. A. (1990)J. Cell Biol. 110, 1333.
Dichter M. A., Tischler A. S., and Greene L. A. (1977)Nature 268, 501.
Dobner P., Kislaukis E., and Bullock B. P. (1992)Ann. NY Acad. Sci. 668, 17.
Foreman P. J., Taglialatela G., Jackson G. R., and Perez-Polo J. R. (1992)J. Neurosci. Res. 31, 52.
Goedert M., Mantyh P. W., Hunt S. P., and Emson P. C. (1984)Brian Res. 299, 389.
Greene L. A. and Tischler A. S. (1976)Proc. Natl. Acad. Sci. USA 73, 2424.
Gudelsky G. A., Berry S. A., and Meltzer H. Y. (1989)Neuroendocrinology 49, 604.
Hökfelt T., Everitt B. J., Theordorson-Norheim E., and Goldstein M. (1984)J. Comp. Neurol. 222, 543.
Icard-Liepkalns C., Faucon Biguet N., Vyas S., Robert J. J., Sassone-Corsi P., and Mallet J. (1992)J. Neurosci. Res. 32, 290.
Kaschow J. and Nemeroff C. B. (1991)Regul. Pept. 36, 153.
Kessler J. P. and Beaudet A. (1989)J. Neurosci. 9, 466.
Kislaukis E. and Dobner P. R. (1990)Neuron 4, 783.
Kislaukis E., Bullock B., McNeil S., and Dobner P. R. (1988)J. Biol. Chem. 263, 4963.
Kitabgi P. and Nemeroff C. B. (1992)Ann. NY Acad. Sci. 668, 1–374.
Kitabgi P., Checler F., Mazella J., and Vincent J. P. (1985)Rev. Clin. Basic Pharmacol. 5, 397.
Lewis E. J., Tank A. W., Weiner N., and Chikaraishi, D. M. (1983)J. Biol. Chem. 258, 14,632.
McEwen B. S., De Kloet E. R., and Rostène W. H. (1986)Physiol. Rev. 66, 1121.
Nordeen S. K., Moyer M. L., and Bona B. J. (1994)Endocrinology 134, 1723.
Obermeier A., Bradshaw R. A., Seedorf K., Choidas A., Schlessinger J., and Ullrich A. (1994)EMBO J. 13, 1585.
Pinnock R. D. (1985)Brain Res. 338, 151.
Porter J. C., Kedzierski W., Aquila-Mansilla, N., and Jorquera B. A. (1990)Endocrinology 126, 2474.
Richter-Landsberg C. and Jastorff B. (1986)J. Cell. Biol. 102, 821.
Rostène W., Brouard A., Dana C., Masuo Y., Agid F., Vial M., et al. (1992)Ann. NY Acad. Sci. 668, 217.
Saadat S., Stehle A. D., Lamouroux A., Mallet J., and Thoenen H. (1987)J. Biol. Chem. 262, 13,007.
Sadoul J. L., Mazella J., Amar S., Kitabgi P., and Vincent J. P. (1984)Biochem. Biophys. Res. Commun. 120, 812.
Scarcériaux V., Pélaprat D., Lhiaubet A. M., Schimpff R. M., Tramu G., and Rostène W. (1994)Dev. Brain Res. 81, 128.
Schimpff R. M., Lhiaubet A. M., Vial M., and Rostène W. (1992)Prog. Neuroendocrinimmunol. 5, 126.
Shi W. X. and Bunney B. S. (1991)Brain Res. 543, 315.
Stephens R. M., Loeb D. M., Coperland T. D., Pawson T., Greelle L. A., and Kaplan D. R. (1994)Neuron 12, 691.
Tischler A. S., Greene L. A., Kwan P. W., and Slayton W. W. (1983)Cell Tissue Res. 228, 641.
Tischler A. S., Lee Y. C., Costopoulos D., Slayton V. W., Jason W. J., and Bloom S. R. (1986)J. Neurosci. 6, 1719.
Tsukada Y., Chiba K., Yamazaki M., and Mohri T. (1994)Biol. Pharm. Bull. 17, 370.
Williams D. L., Newman T. C., Shelness G. S., and Gordon D. A. (1986)Methods Enzymol. 128, 671.
Xu-van Opstal W. Y., Ranger C., Lejeune O., Forgez P., Boudin H., Bisconte J. C., et al. (1994)Microsc. Res. Tech. 28, 440.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Caillaud, T., Opstal, W.Y.Xv., Scarceriaux, V. et al. Treatment of PC12 cells by nerve growth factor, dexamethasone, and forskolin. Mol Neurobiol 10, 105–114 (1995). https://doi.org/10.1007/BF02740670
Issue Date:
DOI: https://doi.org/10.1007/BF02740670